JP2015500797A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015500797A5 JP2015500797A5 JP2014541481A JP2014541481A JP2015500797A5 JP 2015500797 A5 JP2015500797 A5 JP 2015500797A5 JP 2014541481 A JP2014541481 A JP 2014541481A JP 2014541481 A JP2014541481 A JP 2014541481A JP 2015500797 A5 JP2015500797 A5 JP 2015500797A5
- Authority
- JP
- Japan
- Prior art keywords
- glycoprotein
- soluble
- cell
- fusion protein
- effector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000013135 CD52 Antigen Human genes 0.000 claims description 150
- 108010065524 CD52 Antigen Proteins 0.000 claims description 150
- 210000004027 cell Anatomy 0.000 claims description 107
- 108020001507 fusion proteins Proteins 0.000 claims description 53
- 102000037865 fusion proteins Human genes 0.000 claims description 53
- 239000008194 pharmaceutical composition Substances 0.000 claims description 40
- 210000003162 effector t lymphocyte Anatomy 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 39
- 108091033319 polynucleotide Proteins 0.000 claims description 33
- 102000040430 polynucleotide Human genes 0.000 claims description 33
- 239000002157 polynucleotide Substances 0.000 claims description 33
- 239000000523 sample Substances 0.000 claims description 28
- 230000003915 cell function Effects 0.000 claims description 27
- 230000001404 mediated effect Effects 0.000 claims description 27
- 201000010099 disease Diseases 0.000 claims description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 26
- 235000018102 proteins Nutrition 0.000 claims description 23
- 102000004169 proteins and genes Human genes 0.000 claims description 23
- 108090000623 proteins and genes Proteins 0.000 claims description 23
- 150000001720 carbohydrates Chemical class 0.000 claims description 22
- 230000028993 immune response Effects 0.000 claims description 22
- 206010061218 Inflammation Diseases 0.000 claims description 21
- 206010040047 Sepsis Diseases 0.000 claims description 21
- 230000004054 inflammatory process Effects 0.000 claims description 21
- 239000003795 chemical substances by application Substances 0.000 claims description 20
- 239000006143 cell culture medium Substances 0.000 claims description 18
- 150000001413 amino acids Chemical group 0.000 claims description 16
- 230000006870 function Effects 0.000 claims description 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 14
- 235000014633 carbohydrates Nutrition 0.000 claims description 13
- 230000000694 effects Effects 0.000 claims description 12
- 239000000427 antigen Substances 0.000 claims description 9
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 8
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 8
- 238000007877 drug screening Methods 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 238000004113 cell culture Methods 0.000 claims description 7
- 102000036639 antigens Human genes 0.000 claims description 5
- 108091007433 antigens Proteins 0.000 claims description 5
- 235000000346 sugar Nutrition 0.000 claims description 5
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 4
- 229960001230 asparagine Drugs 0.000 claims description 4
- 235000009582 asparagine Nutrition 0.000 claims description 4
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims description 4
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical group NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 claims description 4
- 210000004392 genitalia Anatomy 0.000 claims description 4
- 230000013595 glycosylation Effects 0.000 claims description 4
- 238000006206 glycosylation reaction Methods 0.000 claims description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 4
- 210000004698 lymphocyte Anatomy 0.000 claims description 4
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical group OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 claims description 4
- 229940124606 potential therapeutic agent Drugs 0.000 claims description 4
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 4
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims description 4
- 125000003508 trans-4-hydroxy-L-proline group Chemical group 0.000 claims description 4
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims description 4
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 4
- 208000023275 Autoimmune disease Diseases 0.000 claims description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims description 3
- 150000008163 sugars Chemical class 0.000 claims description 3
- 102000003886 Glycoproteins Human genes 0.000 claims description 2
- 108090000288 Glycoproteins Proteins 0.000 claims description 2
- 102000004877 Insulin Human genes 0.000 claims description 2
- 108090001061 Insulin Proteins 0.000 claims description 2
- 229940127003 anti-diabetic drug Drugs 0.000 claims description 2
- 239000003472 antidiabetic agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229940125396 insulin Drugs 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 108020004999 messenger RNA Proteins 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000013074 reference sample Substances 0.000 claims description 2
- 230000004044 response Effects 0.000 claims 2
- 125000005629 sialic acid group Chemical group 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161560254P | 2011-11-15 | 2011-11-15 | |
| US61/560,254 | 2011-11-15 | ||
| US201261705633P | 2012-09-26 | 2012-09-26 | |
| US61/705,633 | 2012-09-26 | ||
| PCT/AU2012/001411 WO2013071355A1 (en) | 2011-11-15 | 2012-11-15 | Soluble mediator |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015500797A JP2015500797A (ja) | 2015-01-08 |
| JP2015500797A5 true JP2015500797A5 (enExample) | 2015-08-06 |
| JP6004594B2 JP6004594B2 (ja) | 2016-10-12 |
Family
ID=48428838
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014541481A Expired - Fee Related JP6004594B2 (ja) | 2011-11-15 | 2012-11-15 | 可溶性メディエーター |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US9585969B2 (enExample) |
| EP (2) | EP3456338B1 (enExample) |
| JP (1) | JP6004594B2 (enExample) |
| KR (1) | KR102134326B1 (enExample) |
| CN (1) | CN103930123B (enExample) |
| AU (1) | AU2012339618B2 (enExample) |
| BR (1) | BR112014011758A2 (enExample) |
| CA (2) | CA2852133A1 (enExample) |
| ES (2) | ES2703236T3 (enExample) |
| HR (1) | HRP20182001T1 (enExample) |
| LT (1) | LT2750690T (enExample) |
| MX (1) | MX357655B (enExample) |
| PT (1) | PT2750690T (enExample) |
| RU (1) | RU2660580C2 (enExample) |
| SG (1) | SG11201402310SA (enExample) |
| WO (1) | WO2013071355A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX357655B (es) | 2011-11-15 | 2018-07-18 | Walter & Eliza Hall Inst Medical Res | Mediador soluble. |
| WO2013185165A1 (en) * | 2012-06-14 | 2013-12-19 | The Walter And Eliza Hall Institute Of Medical Research | Cd-52 antibodies and their use in determining and enhancing an immune response in a subject |
| AU2013344807B2 (en) * | 2012-11-15 | 2018-05-24 | The Walter And Eliza Hall Institute Of Medical Research | Soluble mediator |
| CA2973529A1 (en) * | 2015-01-26 | 2016-08-04 | Cellectis | Cll1-specific multi-chain chimeric antigen receptor |
| AU2019201584B1 (en) * | 2019-03-07 | 2019-12-05 | Macquarie University | Immunosuppressive glycoforms of soluble cd52 |
| US20220185864A1 (en) * | 2019-03-07 | 2022-06-16 | The Walter And Eliza Hall Institute Of Medical Research | Immunosuppressive glycoforms of soluble cd52 |
| CN111909235B (zh) * | 2019-05-08 | 2022-12-06 | 广西大学 | 一种利用Trans Well小室分离精子释放蛋白的方法 |
| WO2021011678A1 (en) * | 2019-07-15 | 2021-01-21 | Bristol-Myers Squibb Company | Anti-trem-1 antibodies and uses thereof |
| CN114315937B (zh) * | 2022-01-13 | 2024-08-09 | 甘肃智仑新材料科技有限公司 | 一种压驱、压裂用生物质纳米增渗剂及其制备方法和应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8317576D0 (en) | 1983-06-29 | 1983-08-03 | Shaw A S W | Consumer tobacco products |
| US4588580B2 (en) | 1984-07-23 | 1999-02-16 | Alaz Corp | Transdermal administration of fentanyl and device therefor |
| US4904475A (en) | 1985-05-03 | 1990-02-27 | Alza Corporation | Transdermal delivery of drugs from an aqueous reservoir |
| GB8514665D0 (en) | 1985-06-11 | 1985-07-10 | Eroceltique Sa | Oral pharmaceutical composition |
| US4816258A (en) | 1987-02-26 | 1989-03-28 | Alza Corporation | Transdermal contraceptive formulations |
| US4788062A (en) | 1987-02-26 | 1988-11-29 | Alza Corporation | Transdermal administration of progesterone, estradiol esters, and mixtures thereof |
| US4927408A (en) | 1988-10-03 | 1990-05-22 | Alza Corporation | Electrotransport transdermal system |
| US5792294A (en) | 1995-11-16 | 1998-08-11 | Otis Elevator Company | Method of replacing sheave liner |
| AU9399501A (en) * | 2000-10-09 | 2002-04-22 | Isis Innovation | Therapeutic antibodies |
| JP4424987B2 (ja) | 2001-09-20 | 2010-03-03 | ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム | Ｅｌｉｓａアッセイを用いた循環する治療抗体、抗原および抗原／抗体複合体の測定 |
| NZ543654A (en) * | 2003-05-23 | 2009-05-31 | Wyeth Corp | GITR ligand and GITR ligand-related molecules and antibodies and uses thereof |
| EP1636266A2 (en) * | 2003-06-11 | 2006-03-22 | Wyeth a Corporation of the State of Delaware | Platelet glycoprotein ib alpha variant fusion polypeptides and methods of use thereof |
| US20050069958A1 (en) * | 2003-09-26 | 2005-03-31 | Mills Rhonda A. | Method for simultaneous evaluation of a sample containing a cellular target and a soluble analyte |
| JP2007515492A (ja) * | 2003-12-22 | 2007-06-14 | ジェンザイム コーポレイション | 糖尿病の抗ｃｄ５２抗体治療法 |
| WO2008028229A1 (en) * | 2006-09-05 | 2008-03-13 | The Walter And Eliza Hall Institute Of Medical Research | Methods of identifying markers |
| EP2297306B1 (en) | 2008-05-30 | 2016-09-14 | University Of Louisville Research Foundation, Inc. | Human facilitating cells |
| BR112012022342A2 (pt) * | 2010-03-04 | 2017-02-14 | Vet Therapeutics Inc | anticorpos monoclonais dirigidos a cd52 |
| MX357655B (es) * | 2011-11-15 | 2018-07-18 | Walter & Eliza Hall Inst Medical Res | Mediador soluble. |
-
2012
- 2012-11-15 MX MX2014005688A patent/MX357655B/es active IP Right Grant
- 2012-11-15 EP EP18193427.4A patent/EP3456338B1/en active Active
- 2012-11-15 KR KR1020147016049A patent/KR102134326B1/ko not_active Expired - Fee Related
- 2012-11-15 ES ES12850386T patent/ES2703236T3/es active Active
- 2012-11-15 AU AU2012339618A patent/AU2012339618B2/en not_active Ceased
- 2012-11-15 RU RU2014122847A patent/RU2660580C2/ru active
- 2012-11-15 JP JP2014541481A patent/JP6004594B2/ja not_active Expired - Fee Related
- 2012-11-15 PT PT12850386T patent/PT2750690T/pt unknown
- 2012-11-15 US US14/351,501 patent/US9585969B2/en not_active Expired - Fee Related
- 2012-11-15 BR BR112014011758A patent/BR112014011758A2/pt not_active Application Discontinuation
- 2012-11-15 SG SG11201402310SA patent/SG11201402310SA/en unknown
- 2012-11-15 LT LTEP12850386.9T patent/LT2750690T/lt unknown
- 2012-11-15 HR HRP20182001TT patent/HRP20182001T1/hr unknown
- 2012-11-15 WO PCT/AU2012/001411 patent/WO2013071355A1/en not_active Ceased
- 2012-11-15 ES ES18193427T patent/ES2814300T3/es active Active
- 2012-11-15 CN CN201280056027.1A patent/CN103930123B/zh not_active Expired - Fee Related
- 2012-11-15 CA CA2852133A patent/CA2852133A1/en not_active Abandoned
- 2012-11-15 EP EP12850386.9A patent/EP2750690B1/en not_active Not-in-force
-
2013
- 2013-03-25 CA CA2890797A patent/CA2890797C/en active Active
-
2016
- 2016-12-19 US US15/384,137 patent/US10010582B2/en active Active
-
2018
- 2018-05-09 US US15/975,591 patent/US10328124B2/en not_active Expired - Fee Related
- 2018-12-12 US US16/218,287 patent/US10413589B2/en not_active Expired - Fee Related
-
2019
- 2019-08-21 US US16/547,322 patent/US11123403B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015500797A5 (enExample) | ||
| Ries et al. | C-reactive protein apheresis as anti-inflammatory therapy in acute myocardial infarction: results of the CAMI-1 study | |
| Ungerer et al. | Galectin-9 is a suppressor of T and B cells and predicts the immune modulatory potential of mesenchymal stromal cell preparations | |
| Xia et al. | Angiotensin receptor agonistic autoantibodies and hypertension: preeclampsia and beyond | |
| Litwinoff et al. | Emerging targets for therapeutic development in diabetes and its complications: the RAGE signaling pathway | |
| Doganci et al. | The IL-6R α chain controls lung CD4+ CD25+ Treg development and function during allergic airway inflammation in vivo | |
| US8178304B2 (en) | Diagnostic methods relating to Graves' disease and other autoimmune disorders | |
| Shi et al. | Dysregulated Tim-3 expression and its correlation with imbalanced CD4 helper T cell function in ulcerative colitis | |
| JP2013503204A (ja) | Ｂ７−ｈ４融合タンパク質およびその使用方法 | |
| RU2014122847A (ru) | Растворимый медиатор | |
| Li et al. | A galectin-9–driven CD11chigh decidual macrophage subset suppresses uterine vascular remodeling in preeclampsia | |
| JP2012159356A (ja) | 敗血症診断用組合せマーカー | |
| EP3185885B1 (en) | Polypeptides and uses thereof as a drug for treatment of autoimmune disorders | |
| Audemard-Verger et al. | Recruitment of CXCR3+ T cells into injured tissues in adult IgA vasculitis patients correlates with disease activity | |
| BR112020013531A2 (pt) | Uso de anticorpo anti-il-6, por exemplo, clazakizumab para dessensibilização de receptores de transplante de órgãos sólidos e/ou para prevenir, estabilizar ou reduzir rejeição mediada por anticorpos (abmr) | |
| JP2021534195A (ja) | 標的ＴＧＦ−β阻害によるトリプルネガティブ乳がんの処置 | |
| Sabatino Jr et al. | Impact of multiple sclerosis disease-modifying therapies on SARS-CoV-2 vaccine-induced antibody and T cell immunity | |
| JP2024037767A (ja) | 改変型線維芽細胞成長因子２１（ｆｇｆ－２１）を用いる非アルコール性脂肪性肝炎（ｎａｓｈ）の処置方法 | |
| US20130017206A1 (en) | Mcam modulation and uses thereof | |
| US20140271694A1 (en) | Antigen-specific methods of diagnosing and/or treating myocarditis or inflammatory cardiomyopathy | |
| US20040009174A1 (en) | Method of treating asthma | |
| Xia et al. | Selective expression and cellular localization of pro‐inflammatory chemokine ligand/receptor pairs in the sciatic nerves of a severe murine experimental autoimmune neuritis model of Guillain–Barré syndrome | |
| AU2023336565A1 (en) | Medical use of ccr8 antibodies and dosing schedule | |
| CA2759231A1 (en) | Methods for monitoring the efficacy of anti-il-2r antibodies in multiple sclerosis patients | |
| Cao et al. | Elevated serum levels of visfatin in patients with henoch-schönlein purpura |